Strong earnings have been able to counteract all sorts of economic weakness, Jim Cramer told his Mad Money viewers Friday, and that trend is likely to be the case next week as stocks continue their remarkable run to the upside.
Cramer's game plan for next week starts on Monday with earnings from Thor Industries (THO) , the once red-hot recreational vehicle maker that disappointed last quarter. That puts this company in Cramer's penalty box this quarter.
Next, on Tuesday, it's earnings from HD Supply (HDS) , a company that will provide a read on the economy, and Dave & Busters (PLAY) , one of the quintessential experience companies that the millennials love.
Wednesday brings earnings from Brown-Forman (BF.B) . Cramer said he's interested to hear if the company addresses any rumors that rival Constellation Brands (STZ) might be interested in acquiring the company.
For Thursday, it's more earnings, this time from J.M. Smucker (SJM) , a company that's seen tough times lately as price wars rage on in the supermarket aisles. Cramer said he thinks this company could be a buy though, after it reports. Also on Thursday, we hear from Vail Resorts (MTN) , another experiential stock that should perform well.
Finally, on Friday we get the latest U.S. rig count data, showing how falling oil prices are affecting the drillers. Cramer still expects oil to bottom near $43 a barrel and expects U.S. producers to easily fill any gap in demand as the commodity recovers.
Meanwhile, over on Real Money, global equity and income columnist Antonia Oprita says the payrolls data sent a few shivers through the markets. Read more and get a free trial subscription to Real Money.
Executive Decision: Dow Chemical
For his "Executive Decision" segment, Cramer sat down with Andrew Liveris, chairman and CEO of Dow Chemical (DOW) , to talk about climate change and his company's pending tie-up with DuPont (DD) , set to close in August.
Liveris said he's very disappointed by President Trump's decision to leave the Paris Climate Accord. Sustainability is a new business for everyone, he said, and we all need to invest in putting less carbon into the atmosphere. The U.S. is a leader in this area, Liveris continued, and leaders shouldn't leave the table.
As for the pending merger with DuPont, Liveris said that they are almost there in closing the deal and the new companies that will be formed will have incredible synergies and product portfolios. All of these companies, he said, will also be creating American jobs.
Wavering on Lululemon
Sometimes the risk just isn't worth the reward, Cramer told viewers, as he highlighted the incredible quarter just posted by Lululemon Athletica (LULU) , which sent shares soaring up 11.5% today.
Cramer said he missed this quarter's move because he lost conviction after the company missed the numbers last quarter, news that sent shares down from $66 to $50 in a matter of hours. That volatility, Cramer said, was enough to make him back away from the stock.
It turns out, the problems last quarter were exactly as Lulu said -- execution problems. Those problems resolved themselves with new products this quarter, proving once again that Lulu is a movement, not a fad.
Every company makes mistakes, Cramer admitted, but in this case, investors must determine for themselves if they can stomach the volatility those risks create. Even with today's huge move to the upside, the stock has still not returned to where it was a months ago.
For those willing to sign up for Lulu's wild ride, Cramer said he'd be willing to pay under $57 a share.
Executive Decision: Exact Sciences
In his second "Executive Decision" segment, Cramer sat down with Kevin Conroy, chairman, president and CEO at Exact Sciences (EXAS) , to discuss his company's new non-invasive test for colon cancer, Cologuard. Shares of Exact Sciences are up 187% year to date.
Conroy said Cologuard is a "big deal" because it's both easy and accurate, and it brings peace of mind to to everyone who gets a "normal" result from the test. He said that screening and early detection is critical for colon cancer and Cologuard costs just $500, compared to between $1,500 and $5,000 for a traditional colonoscopy procedure.
When asked about his company's pricing strategy, Conroy said that Medicare is the largest payer for Cologuard and Exact Sciences believes that no one should pay less than the government for these tests.
Exact Sciences is also developing a new test to detect pancreatic cancer that uses the same technology as Cologuard, Conroy added.
Cramer said he's a believer in Exact Sciences.
In the Lightning Round, Cramer was bullish on Micron Technology (MU) , Charles River Labs (CRL) , Facebook (FB) , Amazon.com (AMZN) , Netflix (NFLX) , Alphabet (GOOGL) and Advanced Micro Devices (AMD) .
Executive Decision: Nutanix
For his final "Executive Decision" segment, Cramer spoke with Dheeraj Pandey, founder, chairman and CEO of Nutanix (NTNX) , the cloud computing company, shares of which are down 30% so far this year.
Pandey explained that Nutanix helps companies embrace the cloud, which in turn helps them move fast and save money. For clients like Best Buy (BBY) , which was using traditional order and inventory systems, using Nutanix has greatly reduced their IT operating expenses.
Nutanix counts Nasdaq (NDAQ) as a client also, and Pandey said that this company needs systems that are secure, 100% reliable and distributed among its 70 markets around the world.
Cramer said given all the company has going for it, the stock should be much higher.
Cramer and the AAP team have their weekly roundup ready. Find out what they're telling their investment club members about key holdings Hewlett-Packard Enterprises (HPE) , Snap-On (SNA) , Starbucks (SBUX) and more. Get a free trial subscription to Action Alerts PLUS.
Meet the Millennial Media Moguls
Planning to be in New York on Tuesday, June 13? You're invited to join us for an evening of cocktails and conversation with three dynamic young CEOs whose companies have found big news audiences and good markets. How have they done it? What have they learned? Meet Chris Altchek, CEO and co-founder of Mic; Shafqat Islam, co-founder and CEO of NewsCred; and Kathryn Minshew, the CEO and co-founder of TheMuse. Our panel discussion will be led by Ken Doctor, media analyst and columnist for TheStreet. The event, from 6 to 8 p.m., is free but space is limited and reservations are required. Please click here to RSVP and get more information.
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.